Pharma Mar, S.A.

Factors to consider:

• Company pays dividends (irregularly): last record date 2026-07-09, amount 1.14$ (Y1.30%)
• Earnings for 18 months up through Q2 (+1 year) exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

• 2024-12-31 to 2025-12-31 estimated range: [49.12$, 91.28$]
• 2025-12-31 to 2026-12-31 estimated range: [41.50$, 78.69$]

Financial Metrics affecting the PHMMF estimates:

• Negative: with PPE of 52.0 at the end of fiscal year the price was high
• Positive: -4.17 < Operating profit margin, % of 3.70
• Positive: Investing cash flow per share per price, % of 0.08 > -0.65
• Negative: Industry earnings per price (median), % of -15.23 <= 0
• Positive: 0.30 < Operating cash flow per share per price, % of 0.44
• Negative: 0.01 < Interest expense per share per price, % of 0.18
• Positive: 42.34 < Shareholder equity ratio, % of 59.59 <= 63.79
• Negative: negative Industry operating income (median)
• Negative: negative Industry operating cash flow (median)